Latest C-peptide Stories
SAN MATEO, Calif., Sept. 8, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a company focused on the development of novel therapeutics for cardiovascular disease, today announced that Daron Evans, Chief Financial Officer, will present at the Rodman & Renshaw 13th Annual Global Investment Conference on Tuesday, September 13, 2010 at 2:50 p.m. (Eastern Time) at The Waldorf Astoria in New York City, New York.. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage...
LA JOLLA, Calif., Sept. 7, 2011 /PRNewswire/ -- Cebix Incorporated will chair and participate in the symposium, "C-Peptide and the Pathophysiology of Diabetes" on the occasion of the European Association for the Study of Diabetes (EASD) Annual Meeting 2011. Cebix Chief Scientific Officer John Wahren, M.D., Ph.D., and President and CEO James Callaway, Ph.D., along with members of various academic institutions, will present the latest clinical results for C-peptide replacement therapy in...
ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes. Exploratory, post-hoc analyses suggest that teplizumab, an anti-CD3 monoclonal antibody, when used in a 14-day full dose regimen, preserves C-peptide and increases the...
LA JOLLA, Calif., June 24, 2011 /PRNewswire/ -- Cebix Incorporated announced today that preclinical data for its long-acting form of C-peptide, Ersatta(TM) (CBX129801), demonstrated a half-life of three days as compared to one hour for native C-peptide. Ersatta halted the impairment in nerve conduction velocity, a measure of the rate at which electrical signals travel through the nerves, in an animal model of diabetic peripheral neuropathy. Additionally, clinical data showed that native...
HYDERABAD, India, June 22, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will unveil its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego June 25-30, 2011. "It is fitting that we formally launch our new...
CRANBURY, N.J., June 21, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs." The claims in the issued patent cover a series of small molecule mimics for naturally occurring amino acids which can be used as building blocks in drug development. A small molecule mimic claimed in the issued patent is used in making PL-3994, Palatin's...
LA JOLLA, Calif., June 16, 2011 /PRNewswire/ -- Cebix Incorporated announced today it is advancing the development of modified C-peptide for the treatment of complications of diabetes. The biopharmaceutical company has initiated a Phase 1b clinical trial to evaluate Ersatta(TM), its proprietary long-acting form of C-peptide, in patients with type 1 diabetes who, because of their disease, lack this endogenous peptide. Following the successful completion of this study, the company is...
PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/ -- Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery. Under the terms of the agreement, Pepscan using...
WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes. The study, entitled: "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism...
LELYSTAD, The Netherlands, April 4, 2011 /PRNewswire/ -- Pepscan Therapeutics, the Dutch biotech company focusing on protein mimicry for the discovery of therapeutics peptides and antibodies, announced today the appointment of Michiel Lodder as Chief Business Officer. Dr. Lodder joins Pepscan from Octoplus, where he held the position of Senior Manager Business Development, responsible for licensing, partnering, and alliance management activities. "We are delighted to bring Michiel...
